No abstract

Background and Objectives Implementation of automated steps in preparing blood components for transfusion from whole blood collections has produced improvements in multiple fields. The aim of this review is to summarize data from existing literature related to automation of whole blood processing systems. Materials and Methods We searched MEDLINE for studies comparing semi‐automated and fully automated whole blood processing systems published before 20 July 2021. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were followed. Additionally, we performed a manual search. Results We identified 500 studies, of which 459 (92%) did not meet the eligibility criteria, and finally 17 studies were included in the analysis. Manual search included six additional studies. Publication year ranged from 2004 to 2021. Automation reduced the run‐time (from 92 to 76 min), improved recovery of haemoglobin in red cell concentrates (RCCs) and resulted in higher red blood cell and platelet yields. Automation also reduced discard rates due to whole blood bag ruptures (1.2%–0.1%), low volume of RCCs (<200 ml; 0.5%–0.03%) and haemolytic plasma (2.1%–0.6%). Automation could reduce the number of full‐time equivalent (FTE) operators or maintain the number of FTE operators while performing additional procedures, and it reduced to 1.13 m2 the space required for the device. Conclusion Automation of whole blood processing resulted in continued improvements in productivity, product quality and technical features. However, too few publications are available to reach strong conclusions. Therefore, it is necessary to expand the scientific knowledge in this field.

Objectives: Upper limb loss greatly impacts one's productivity and quality of life. Despite a wealth of prosthetic device options, high user dissatisfaction and rejection rates persist. Novel connective and control methods between a device and end-user VALUE IN HEALTH - MAY 2019

Objectives: Recent epidemiological and cost analyses show statistically significant associations between hypotension during ICU stay with death, acute kidney injury (AKI) and hospital costs at MAP levels below 65mmHg. This analysis estimates the associated cost savings per ICU patient that accrue to US hospitals as a result of improved hypotension control between MAP of 65 mmHg and 85 mmHg. Methods: In our economic analysis we estimated patient-level costs associated with hypotension reduction in septic ICU patients from the hospital perspective. The reduction in the probabilities of AKI and death were sourced from a prior EMR (Electronic Medical Records) analysis in which hypotension exposure was defined by timeweighted average mean arterial pressure (TWA-MAP). Our analysis focused on TWA-MAP levels between 65-85 mmHg. Cost savings for each of the separate outcomes in sepsis was estimated from the current published literature. All dollars were adjusted to reflect 2018 costs. Scenario analyses and Monte Carlo simulations were performed to test the robustness of the model. We also developed a second model as a robustness check. Results: For our main model, we ran two simulations (10,000 trials each). These models compared expected cost difference in A) 65 vs. 75 TWA-MPA mmHg and B) 75 vs. 85 TWA-MAP mmHg hypothetical patients. Cost savings were A

No abstract